D-0934-2020 Class II Terminated

Recalled by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical — Los Angeles, CA

Recall Details

Product Type
Drugs
Report Date
March 11, 2020
Initiation Date
January 15, 2020
Termination Date
December 7, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
N/A

Product Description

Alprostadil/Papaverine Hydrochloride/Phentolamine Mesylate/Atropine Sulfate Injection, 60 mcg/30 mg/2 mg/0.15mg/ml, For Intracavernosal Use, Freeze, 2.5 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0550-2

Reason for Recall

Lack of Assurance of Sterility

Distribution Pattern

U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic

Code Information

Lot #: 12042019+53323, Exp 1/17/2020